Blocking Pyk2 to help immune therapy work better for glioblastoma
Pyk2 inhibition mitigates immunosuppressive environment and enhances therapeutic response to immune checkpoint inhibitors in GBM
['FUNDING_OTHER'] · UNIVERSIDAD CENTRAL DEL CARIBE · NIH-11325413
Seeing if stopping a protein called Pyk2 can make immune checkpoint drugs (like PD-L1 blockers) work better for people with glioblastoma.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSIDAD CENTRAL DEL CARIBE (nih funded) |
| Locations | 1 site (BAYAMON, UNITED STATES) |
| Trial ID | NIH-11325413 on ClinicalTrials.gov |
What this research studies
Researchers will study human glioblastoma tumors and lab models to see how Pyk2 and related FAK signaling shape the tumor's immune environment. They will reduce Pyk2/FAK activity using genetic and pharmacologic approaches and measure immune cells such as tumor-infiltrating myeloid cells and CD8+ T cells. They will test combining Pyk2 targeting with PD-L1 immune checkpoint blockade in preclinical models to see if that combination improves anti-tumor responses. The work aims to identify treatment strategies that could make immunotherapy more effective for glioblastoma patients.
Who could benefit from this research
Good fit: People with glioblastoma, particularly those with recurrent disease or tumors showing Pyk2/FAK activity, would be the most relevant candidates for related clinical efforts.
Not a fit: Patients with brain conditions other than glioblastoma or whose tumors lack Pyk2/FAK activity are unlikely to benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could increase the number of glioblastoma patients who respond to immune checkpoint therapies or improve their outcomes.
How similar studies have performed: Immune checkpoint drugs have had very limited success in glioblastoma so far, and targeting Pyk2/FAK is a newer preclinical strategy with promising laboratory signals but not yet proven in patients.
Where this research is happening
BAYAMON, UNITED STATES
- UNIVERSIDAD CENTRAL DEL CARIBE — BAYAMON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KUCHERYAVYKH, LILIA — UNIVERSIDAD CENTRAL DEL CARIBE
- Study coordinator: KUCHERYAVYKH, LILIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Brain Cancer